These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23951304)

  • 1. Interferon-gamma increases the ratio of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in peripheral monocytes from patients with coronary artery disease.
    Springall R; Amezcua-Guerra LM; Gonzalez-Pacheco H; Furuzawa-Carballeda J; Gomez-Garcia L; Marquez-Velasco R; Mejía-Domínguez AM; Cossío-Aranda J; Martínez-Sánchez C; Bojalil R
    PLoS One; 2013; 8(8):e72291. PubMed ID: 23951304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum of Patients with Psoriasis Modulates the Production of MMP-9 and TIMP-1 in Cells of Monocytic Lineage.
    Amezcua-Guerra LM; Bojalil R; Espinoza-Hernandez J; Vega-Memije ME; Lacy-Niebla RM; Ortega-Springall F; Ortega-Hernández J; Sánchez-Muñoz F; Springall R
    Immunol Invest; 2018 Oct; 47(7):725-734. PubMed ID: 29979898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome.
    Cheng M; Hashmi S; Mao X; Zeng QT
    Can J Cardiol; 2008 May; 24(5):385-90. PubMed ID: 18464944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease.
    Fitzsimmons PJ; Forough R; Lawrence ME; Gantt DS; Rajab MH; Kim H; Weylie B; Spiekerman AM; Dehmer GJ
    Atherosclerosis; 2007 Sep; 194(1):196-203. PubMed ID: 16942771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of PPAR-gamma agonist rosiglitazone on MMP-9 and TIMP-1 expression of monocyte-derived macrophages isolated from patients with acute coronary syndrome].
    Luo YM; Wan XH; Jiang DQ; Kuang WY; Guo HB; Chen ZX; Wang HJ; Xie LH; Duan W
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Aug; 37(8):739-45. PubMed ID: 20021931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood levels of matrix and inflammatory mediators are elevated in Tunisian patients with acute coronary syndromes.
    Zayani Y; Allal-Elasmi M; Jacob MP; Zidi W; Zaroui A; Feki M; Mourali S; Mechmech R; Kaabachi N
    Clin Lab; 2013; 59(1-2):169-75. PubMed ID: 23505923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
    Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
    Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of matrix metalloproteinase and their inhibitors on atrial myocardial structural remodeling.
    Wang W; Zhang HT; Yang XL
    J Cardiovasc Med (Hagerstown); 2013 Apr; 14(4):265-9. PubMed ID: 22929563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcription activity of MMP-2 and MMP-9 metalloproteinase genes and their tissue inhibitor (TIMP-2) in acute coronary syndrome patients.
    Dabek J; Glogowska-Ligus J; Szadorska B
    J Postgrad Med; 2013; 59(2):115-20. PubMed ID: 23793312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
    Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
    Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios.
    Pérez P; Kwon YJ; Alliende C; Leyton L; Aguilera S; Molina C; Labra C; Julio M; Leyton C; González MJ
    Arthritis Rheum; 2005 Sep; 52(9):2751-60. PubMed ID: 16142742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro effect of caffeic acid phenethyl ester on matrix metalloproteinases (MMP-1 and MMP-9) and their inhibitor (TIMP-1) in lipopolysaccharide-activated human monocytes.
    Vilela Pd; de Oliveira JR; de Barros PP; Leão MV; de Oliveira LD; Jorge AO
    Arch Oral Biol; 2015 Sep; 60(9):1196-202. PubMed ID: 26058005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers.
    Giansante C; Fiotti N; Di Chiara A; Altamura N; Wasserman S; Fioretti P; Guarnieri G
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):602-7. PubMed ID: 17667031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study.
    Kuliczkowski W; Radomski M; Gąsior M; Urbaniak J; Kaczmarski J; Mysiak A; Negrusz-Kawecka M; Bil-Lula I
    Biomed Res Int; 2017; 2017():9352015. PubMed ID: 28770228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EFFECT OF RELATIVE GENE EXPRESSION ON PLAQUE VULNERABILITY IN PATIENTS WITH STABLE ANGINA AND PATIENTS WITH ACUTE CORONARY SYNDROME.
    Chen N; Zhang JY; Yang SZ; Li YD
    J Biol Regul Homeost Agents; 2015; 29(2):437-41. PubMed ID: 26122234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases (MMP-8, MMP-9) and the tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2) in patients with fungal keratitis.
    Rohini G; Murugeswari P; Prajna NV; Lalitha P; Muthukkaruppan V
    Cornea; 2007 Feb; 26(2):207-11. PubMed ID: 17251814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of 1, 25 dihydroxyvitamin D(3) on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis.
    Anand SP; Selvaraj P
    Clin Immunol; 2009 Oct; 133(1):126-31. PubMed ID: 19615945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.